<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-K6GE81NM</identifier><date>2023</date><creator>Pašić, Lejla</creator><relation>documents/doc/K/URN_NBN_SI_doc-K6GE81NM_001.pdf</relation><relation>documents/doc/K/URN_NBN_SI_doc-K6GE81NM_001.txt</relation><format format_type="issue">5</format><format format_type="volume">74</format><format format_type="type">article</format><format format_type="extent">str. 372-373</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID">190571011</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-K6GE81NM</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">cepivo</subject><subject language_type_id="slv">farmacija</subject><subject language_type_id="slv">SARS-CoV-2</subject><title>EMA priporoča odobritev prilagojenega Nuvaxovid Covid-19 cepiva</title></Record>